Throughout 2022, ACHP worked closely with its member companies and remained focused on ensuring adults and children in communities across the country gained and maintained affordable, high-value health coverage and care.

• Provided critical information that led to a Senate Finance Committee investigation and report about inappropriate and misleading Medicare Advantage (MA) marketing abuses. Following the report’s publication, CMS announced it will increase oversight of aggressive marketing behaviors.
• Extended enhanced ACA tax credits for three years – through 2025 – ensuring millions of Americans will maintain access to quality, affordable health coverage.
• Remained the only national payer organization to push Congress and the Administration for comprehensive drug pricing reform.
  • Lobbied successfully for the passage of the Inflation Reduction Act (IRA), a “win for consumers.”
  • Aggressively pushed the Biden Administration to limit coverage of controversial drug Aduhelm to Medicare beneficiaries participating in clinical trials.
    • Limiting coverage of Aduhelm led to the largest decrease in Medicare Part B premiums in a decade. Monthly premiums will drop 3.1% in 2023.
• Successfully advocated to protect the MA program and received an 8.5% MA rate bump in the 2023 Rate Notice.
• Worked with the Biden Administration to shape over-the-counter COVID testing requirements, ensuring equitable and affordable access to life-saving tests.
• Shaped end-of-year spending bill, which included key ACHP priorities, such as:
  • Extensions on: the Acute Hospital Care at Home waiver; telehealth flexibilities tied to the public health emergency including a delay of the in-person requirement to receive telemental health care; and enhanced Medicaid payments for states that meet reporting requirements
  • 12 months of continuous coverage for children in Medicaid and CHIP
  • Flexibility for states to provide up to 12 months of post-partum coverage.